07.20.18
Headquarters: Osaka, Japan
twitter.com/TakedaPharmaDe
www.takeda.com
Headcount: 27,230
Year Established: 1781
Revenues: $16,663 (+2%)
Net Income: $1,757 (+62%)
R&D: $306 (+4%)
Top Selling Drugs
This past year was rather eventful by way of collaborations, acquisitions, and facility openings for Takeda. The company completed construction of new manufacturing facilities at its site in Oranienburg, Germany. The €100 million site aims to deliver high-quality medicines to more patients in a timely manner, as well as further address patients’ needs, and began operations at the end of 2017. In addition, Takeda also held the grand opening of its new Global Headquarters in Nihonbashi, Tokyo, Japan. The massive building was completed in March 2018, and will serve as Takeda’s head office for its operations worldwide, as well as a home base for its more than 30,000 employees across the globe.
Within collaborations, Takeda and Biological E. Ltd. entered into a partnership to expedite the development and delivery of affordable combination vaccines to low and middle income countries across the world. In another collaboration, Takeda joined Cardurion Pharmaceuticals in the creation of a new cardiovascular development partnership, in which Takeda provided Cardurion with a 12-person research team, including fully equipped lab space, development resources and licenses to a portfolio of preclinical cardiovascular drug programs. Takeda also partnered with TESARO to develop and commercialize novel cancer therapy, Niraparib, in Japan, and with Molecular Templates to develop next-generation oncology therapies. Takeda and BioSurfaces also entered a joint research program to explore treatments for gastrointestinal diseases.
In the acquisition space, Takeda’s acquisition of TiGenix for $628 million closed in June 2018. Finally, in the largest-ever foreign takeover by a Japanese company, Takeda acquired Shire for $62 billion, capping a months-long battle of offer rejections. At press time Takeda announced plans to sell its Osaka headquarters to help bolster its finances. The sale is expected to raise approximately $542 million. Chief executive officer Christophe Weber said the company plans to keep its headquarters in Japan after the merger with Shire. The ambitious acquisition is not without concerns among investors, as stock prices have fallen more than 20% since intentions of the deal emerged.
twitter.com/TakedaPharmaDe
www.takeda.com
Headcount: 27,230
Year Established: 1781
Revenues: $16,663 (+2%)
Net Income: $1,757 (+62%)
R&D: $306 (+4%)
Top Selling Drugs
Drug | Indication | 2017 Sales | (+/-%) |
Entyvio | ulcerative colitis,Crohn’s disease | $1,896 | 41% |
Velcade | multiple myeloma | $1,292 | 0% |
Leuprorelin | prostate cancer, breast cancer, endometriosis | $1,077 | 0% |
Takecab | acid-related diseases | $519 | 62% |
Trintellix | anti-depressant | $456 | 52% |
Ninlaro | multiple myeloma | $437 | 58% |
Adcetris | Hodgkin lymphoma | $362 | 28% |
This past year was rather eventful by way of collaborations, acquisitions, and facility openings for Takeda. The company completed construction of new manufacturing facilities at its site in Oranienburg, Germany. The €100 million site aims to deliver high-quality medicines to more patients in a timely manner, as well as further address patients’ needs, and began operations at the end of 2017. In addition, Takeda also held the grand opening of its new Global Headquarters in Nihonbashi, Tokyo, Japan. The massive building was completed in March 2018, and will serve as Takeda’s head office for its operations worldwide, as well as a home base for its more than 30,000 employees across the globe.
Within collaborations, Takeda and Biological E. Ltd. entered into a partnership to expedite the development and delivery of affordable combination vaccines to low and middle income countries across the world. In another collaboration, Takeda joined Cardurion Pharmaceuticals in the creation of a new cardiovascular development partnership, in which Takeda provided Cardurion with a 12-person research team, including fully equipped lab space, development resources and licenses to a portfolio of preclinical cardiovascular drug programs. Takeda also partnered with TESARO to develop and commercialize novel cancer therapy, Niraparib, in Japan, and with Molecular Templates to develop next-generation oncology therapies. Takeda and BioSurfaces also entered a joint research program to explore treatments for gastrointestinal diseases.
In the acquisition space, Takeda’s acquisition of TiGenix for $628 million closed in June 2018. Finally, in the largest-ever foreign takeover by a Japanese company, Takeda acquired Shire for $62 billion, capping a months-long battle of offer rejections. At press time Takeda announced plans to sell its Osaka headquarters to help bolster its finances. The sale is expected to raise approximately $542 million. Chief executive officer Christophe Weber said the company plans to keep its headquarters in Japan after the merger with Shire. The ambitious acquisition is not without concerns among investors, as stock prices have fallen more than 20% since intentions of the deal emerged.